Review



the primary anti‐pd‐l1 antibody (clone sp142;  (Spring Bioscience)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Spring Bioscience the primary anti‐pd‐l1 antibody (clone sp142;
    The Primary Anti‐Pd‐L1 Antibody (Clone Sp142;, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+primary+anti+pd+l1+antibody+(clone+sp142%3B/sp142+antibody/pmc05406530-64-7-11
    Average 90 stars, based on 1 article reviews
    the primary anti‐pd‐l1 antibody (clone sp142; - by Bioz Stars, 2026-09
    90/100 stars

    Images



    Similar Products

    anti-pd-l1 primary antibody clone sp142  (ZSGB Biotech)
    90
    ZSGB Biotech anti-pd-l1 primary antibody clone sp142
    Association between <t> PD-L1 </t> expression and clinicopathological features of patients with NPC.
    Anti Pd L1 Primary Antibody Clone Sp142, supplied by ZSGB Biotech, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+primary+anti+pd+l1+antibody+(clone+sp142%3B/sp142/pmc08804341-91-8-13
    Average 90 stars, based on 1 article reviews
    anti-pd-l1 primary antibody clone sp142 - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier
    the primary anti‐pd‐l1 antibody (clone sp142;  (Spring Bioscience)
    90
    Spring Bioscience the primary anti‐pd‐l1 antibody (clone sp142;
    Association between <t> PD-L1 </t> expression and clinicopathological features of patients with NPC.
    The Primary Anti‐Pd‐L1 Antibody (Clone Sp142;, supplied by Spring Bioscience, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/the+primary+anti+pd+l1+antibody+(clone+sp142%3B/sp142+antibody/pmc05406530-64-7-11
    Average 90 stars, based on 1 article reviews
    the primary anti‐pd‐l1 antibody (clone sp142; - by Bioz Stars, 2026-09
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Association between PD-L1 expression and clinicopathological features of patients with NPC.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Association between PD-L1 expression and clinicopathological features of patients with NPC.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing

    Representative immunohistochemistry of (A) negative, (B) weak, (C) moderate, and (D) strong PD-L1 staining in NPC tumor tissues. All the images are 40X magnification, The definition of negative was no staining, weak staining was yellow particles, moderate staining was yellow–brown, and strong staining was brown.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Representative immunohistochemistry of (A) negative, (B) weak, (C) moderate, and (D) strong PD-L1 staining in NPC tumor tissues. All the images are 40X magnification, The definition of negative was no staining, weak staining was yellow particles, moderate staining was yellow–brown, and strong staining was brown.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Immunohistochemistry, Staining

    (A) Percentage of metastatic and non-metastatic NPC patients with high PD-L1 expression levels at diagnosis. (B) Percentage of metastatic and non-metastatic NPC patients who were EBV-positive at diagnosis.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: (A) Percentage of metastatic and non-metastatic NPC patients with high PD-L1 expression levels at diagnosis. (B) Percentage of metastatic and non-metastatic NPC patients who were EBV-positive at diagnosis.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing, Biomarker Discovery

    Evaluation of progression-free survival using the Kaplan-Meier survival analysis. (A) Patients with high PD-L1 expression is associated with shorter progression-free survival; (B) Patients with positive EBV status is associated with shorter progression-free survival; (C, D) Progression-free survival based on both PD-L1 expression levels and EBV status indicated that patients with high PD-L1 expression and positive EBV status is associated with shortest progression-free survival.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Evaluation of progression-free survival using the Kaplan-Meier survival analysis. (A) Patients with high PD-L1 expression is associated with shorter progression-free survival; (B) Patients with positive EBV status is associated with shorter progression-free survival; (C, D) Progression-free survival based on both PD-L1 expression levels and EBV status indicated that patients with high PD-L1 expression and positive EBV status is associated with shortest progression-free survival.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing

    Evaluation of overall survival using the Kaplan-Meier survival analysis. No overall survival difference is noted in NPC patients stratified according to PD-L1 expression, EBV status, and their combination. (A) Overall survival based on tumoral PD-L1 expression alone; (B) Overall survival based on EBV status alone; (C, D) Overall survival based on PD-L1 expression levels and EBV status.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Evaluation of overall survival using the Kaplan-Meier survival analysis. No overall survival difference is noted in NPC patients stratified according to PD-L1 expression, EBV status, and their combination. (A) Overall survival based on tumoral PD-L1 expression alone; (B) Overall survival based on EBV status alone; (C, D) Overall survival based on PD-L1 expression levels and EBV status.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing

    Univariate analysis of progression-free survival in patients with NPC.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Univariate analysis of progression-free survival in patients with NPC.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing

    Multivariate analysis of progression-free survival in patients with NPC.

    Journal: Frontiers in Oncology

    Article Title: Combined Association of Tumoral PD-L1 Expression and Pretreatment Presence of Epstein-Barr Virus DNA With Risk Stratification and Prognosis of Patients With Nasopharyngeal Carcinoma

    doi: 10.3389/fonc.2021.791411

    Figure Lengend Snippet: Multivariate analysis of progression-free survival in patients with NPC.

    Article Snippet: The sections were stained overnight at 4°C with anti-PD-L1 primary antibody (clone SP142, ZSGB-Bio, Beijing, China), followed by incubation with secondary antibody for 45 min at 37°C and immunoreactions were visualized using the ChemMate EnVision+ detection kit (Peroxidase/Dab, Rabbit/Mouse, K5007, Dako, Glostrup, Denmark).

    Techniques: Expressing